Caprock Group LLC Has $201,000 Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Caprock Group LLC reduced its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 68.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,861 shares of the medical equipment provider’s stock after selling 3,976 shares during the quarter. Caprock Group LLC’s holdings in Zimmer Biomet were worth $201,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Ashton Thomas Securities LLC acquired a new position in Zimmer Biomet during the third quarter valued at $28,000. Bangor Savings Bank purchased a new position in Zimmer Biomet during the 3rd quarter valued at about $31,000. Family Firm Inc. purchased a new stake in shares of Zimmer Biomet in the second quarter worth approximately $33,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in shares of Zimmer Biomet in the second quarter worth approximately $43,000. Finally, Ridgewood Investments LLC acquired a new stake in shares of Zimmer Biomet during the second quarter worth approximately $43,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

ZBH has been the topic of several research reports. TD Cowen dropped their price objective on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating on the stock in a research note on Friday, September 6th. Raymond James dropped their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. Wells Fargo & Company boosted their target price on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Canaccord Genuity Group dropped their target price on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research report on Tuesday, September 10th. Finally, Truist Financial boosted their price target on Zimmer Biomet from $112.00 to $117.00 and gave the company a “hold” rating in a research note on Friday, November 1st. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $123.22.

Zimmer Biomet Stock Performance

ZBH opened at $110.22 on Monday. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The stock’s 50 day moving average price is $106.79 and its two-hundred day moving average price is $109.62. The firm has a market capitalization of $21.94 billion, a P/E ratio of 20.95, a price-to-earnings-growth ratio of 2.03 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same quarter in the previous year, the firm posted $1.65 earnings per share. Zimmer Biomet’s revenue was up 4.1% compared to the same quarter last year. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.87%. Zimmer Biomet’s dividend payout ratio is 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.